Engineering enhanced CAR T-cells for improved cancer therapy

Nat Cancer. 2021 Aug;2(8):780-793. doi: 10.1038/s43018-021-00241-5. Epub 2021 Aug 19.


Chimeric antigen receptor (CAR) T-cell therapies have evolved from a research tool to a paradigm-shifting therapy with impressive responses in B cell malignancies. This review summarizes the current state of the CAR T-cell field, focusing on CD19- and B cell maturation antigen-directed CAR T-cells, the most developed of the CAR T-cell therapies. We discuss the many challenges to CAR-T therapeutic success and innovations in CAR design and T-cell engineering aimed at extending this therapeutic platform beyond hematologic malignancies.

Keywords: CAR; T cell; antigen; cancer; chimeric.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antigens, CD19
  • Humans
  • Immunotherapy, Adoptive
  • Neoplasms* / therapy
  • Receptors, Chimeric Antigen*
  • T-Lymphocytes


  • Antigens, CD19
  • Receptors, Chimeric Antigen